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Abstract
Background: We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination
ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our
knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique
management challenges for both the melanoma and the immunotherapy-related toxicity.
Case presentation: A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/
nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic
findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy
tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the
granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration.
Conclusions: Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide
decision making, as non-melanoma lesions can mimic disease progression.
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Background
The treatment options for metastatic melanoma have
improved dramatically with the advent of novel im-
munotherapies, specifically checkpoint inhibitors. Such
agents include ipilimumab, a fully humanized monoclo-
nal antibody against cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4), as well as nivolumab and pembroli-
zumab, IgG4 anti-programmed-death 1 (anti-PD1) im-
mune checkpoint inhibitor antibodies [1–4]. Prior to the
approval of these agents, FDA-approved therapies for
melanoma were limited by toxicity and low efficacy.
Currently, initial therapy for many newly-diagnosed
patients with advanced melanoma is either anti-PD1
monotherapy or the combination of ipilimumab and
nivolumab [3, 4]. The novel mechanisms of action of
checkpoint inhibitors have resulted in a unique set of side
effects, so called immune-related adverse events (irAEs).
These toxicities can involve any organ system, though
most commonly skin, gastrointestinal tract, and the endo-
crine system [1–4]. While less frequent, interstitial lung
disease and pneumonitis have been documented [2, 3].
Sarcoidosis and sarcoid-like granulomatosis have been
reported in melanoma patients treated with single
agent ipilimumab and single-agent anti-PD1 therapy
(Table 1) [5–14]. Sarcoid development has also been
reported in sarcoma patients managed with pembroli-
zumab [15]. Given that development of sarcoidosis
can mimic disease progression, accurate identification
of this process is imperative. We report the first
known case, to our knowledge, of tumefactive sar-
coidosis following combination treatment with ipili-
mumab and nivolumab in a patient with metastatic
melanoma, highlighting the importance of tissue diag-
nosis and raising management challenges.
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Case presentation
A 32-year-old female was diagnosed with pT3bN0M0,
stage IIB, melanoma of the left anterior distal thigh in
2001. She was managed with wide excision, and sentinel
lymph node evaluation was negative. The patient was
observed and remained free of disease until 2015 when
she presented to her dermatologist with subcutaneous
lesions in the left groin and upper back. Punch biopsy of
a left inguinal nodule demonstrated BRAF wild-type ma-
lignant melanoma. Diagnostic imaging with PET/CT and
brain MRI demonstrated brain metastases, pulmonary
nodules, left hilar and subcarinal lymphadenopathy, liver
metastases, and several bone and soft tissue lesions
(Figs. 1 and 2). Brain lesions were managed with Gamma
Knife radiosurgery with good tolerance.
She commenced combination immunotherapy treat-
ment with ipilimumab 3 mg/kg and nivolumab 1 mg/kg
every 3 weeks. After the four combination doses, im-
aging demonstrated improvement in soft tissue disease,
pulmonary and liver lesions, as well as brain metastases.
The baseline subcarinal and left hilar adenopathy did
not change in size. Treatment was well tolerated with
grade 1 diarrhea, nausea, and rash, as well as the devel-
opment of hypothyroidism requiring supplementation.
She was transitioned to maintenance nivolumab 3 mg/kg
every 2 weeks.
Table 1 Cases of immunotherapy induced sarcoid and sarcoid-like granulomatous reaction in metastatic melanoma
Age*, Sex Stage Immunotherapy (cycle










67 F IV Ipilimumab (4+) stable disease lung, mediastinum, skin dyspnea unknown [5]
62 F IV Ipilimumab (not reported) stable disease mediastinal LN, skin,
bronchus
none No [6]
49 M IV Ipilimumab (4) complete response mediastinal/hilar LN none N0 [7]




Yes - steroids [8]
63 M IV Ipilimumab (4) progression lung dyspnea, dry cough,
hypoxia
Yes-steroids [9]
57 M IIIB Ipilimumab (6) Unknown lung, hilar LN, skin none No [10]
55 M IIIB Ipilimumab (2) progression lung, mediastinal/
hilar LN, skin
dyspnea, hypoxia Yes-steroids [11]






44 M IV Ipilimumab (4) partial response spleen none No [13]
57 M IV Nivolumab (not reported) complete response mediastinal/hilar
LN, skin
none No [14]
*Age at initial diagnosis of melanoma
Fig. 1 Imaging at Time of Diagnosis Before Treatment. a Scout PET scan showing cervical/mediastinal/inguinal adenopathy and vertebral lesions.
b Cross section of mediastinum with increased update in mediastinal nodes (SUVmax 10 in subcarinal node). c Cross section of knees with no
increased uptake. d MRI brain with two right cerebellar metastases with vasogenic edema
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Prior to cycle 1 of maintenance nivolumab, she devel-
oped a scaly lesion of left pretibial skin and underlying
subcutis, which grew after her first treatment. Fine
needle aspiration (FNA) of the lesion revealed non-
caseating granulomatous inflammation without evidence
of malignancy. Given the proximity to her primary lesion
and history of subcutaneous melanoma metastases, a
PET-CT scan was performed. The left pretibial lesion
was FDG-avid, and the scans also revealed new supracla-
vicular, mediastinal, right hilar and left iliac adenopathy,
as well as subcutaneous left pretibial and right calf nod-
ules (Fig. 3). The baseline subcarinal and left hilar
lymphadenopathy had increased in size, but the hepatic,
soft tissue, and brain lesions had resolved (Fig. 3).
Given the mixed clinical and radiographic results, ex-
cisional biopsy of the left pretibial lesion was performed
and revealed non-necrotizing granulomatous inflamma-
tion consistent with tumefactive sarcoidal granulomas
(Fig. 4). In addition, endobronchial ultrasound with FNA
of 11R hilar and station 7 subcarinal lymph nodes both
demonstrated granulomatous inflammation without evi-
dence of malignancy. AFB, bacterial, and fungal cultures
showed no growth. In further support of a diagnosis of
sarcoidosis, angiotensin converting enzyme (ACE) level
was elevated to 73 U/L (normal 8–52 U/L). To obtain
preliminary information on the mechanism for growth
of sarcoid lesions in the setting of PD-1 blockade, the
skin biopsy tissue was stained for PD-L1 expression, and
Fig. 2 PET-CT of Hepatic Metastases Before and After Combination Immunotherapy. a PET-CT scan at times of diagnosis of with several
hypermetabolic hepatic lesions consistent with metastases. b PET-CT scan after 4 cycles of nivolumab plus ipilimumab and 3 cycles of
nivolumab maintenance
Fig. 3 PET-CT scan after Nivolumab + Ipilimumab Induction and on Maintenance Nivolumab. a Scout PET scan showing cervical/mediastinal/
inguinal adenopathy and vertebral lesions. b Cross section of mediastinum with increased uptake in mediastinal nodes (SUVmax 16 in paratracheal
node). c Cross section of knees with increased uptake in left soft tissue nodule (SUVmax 2.7). d MRI brain with interval improvement of right
cerebellar metastases
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demonstrated strong PD-L1 staining of the histiocytes
and lymphocytes within the granulomas (Fig. 5).
Throughout this evaluation, she remained asymptomatic
with normal electrocardiogram and pulmonary function
testing. Initially, the decision was made to hold immuno-
therapy without instituting steroids. After 6 weeks, no
new clinical lesions or symptoms appeared and there were
no changes in size or extent of the lymphadenopathy.
With discussion of the risks and benefits of further treat-
ment, she preferred to resume therapy with single agent
nivolumab. At the time of this report, she remains on
nivolumab monotherapy with good tolerance and melan-
oma control. The thoracic lymphadenopathy is stable and
no new lesions or clinical symptoms have developed.
Conclusions
The diagnosis of sarcoidosis in melanoma patients has
been made in a diverse array of clinical settings, includ-
ing sequential and/or concurrent diagnoses, and following
initiation of anti-melanoma therapy. To date, sarcoidosis
development has been reported in untreated melan-
oma patients and those managed with interferon, pep-
tide vaccine, vemurafenib, ipilimumab and nivolumab
[5–14, 16–21]. To our knowledge, this is the first re-
ported incident of sarcoidosis with combination ipili-
mumab and nivolumab immunotherapy.
Recent data suggest an incidence of sarcoidosis in melan-
oma patients of roughly 0.58%, which is substantially
higher than the 0.005% incidence of the general population
Fig. 4 Hematoxylin and Eosin Staining of Pre-Tibial Soft Tissue Nodule. Microscopic hematoxylin and eosin (H&E) section showing (A) large, deep
dermal collections of non-caseating granulomas (a, 2×) extending into the subcutaneous tissue (b, 2×). Higher magnification shows tightly
formed granulomas containing multinucleated giant cells separated by fibrous connective tissue (c, 4×). Scattered mature appearing lymphocytes
are seen surrounding the granulomatous inflammation (d, 10×)
Fig. 5 PD-L1 Staining of Pre-Tibial Soft Tissue Nodule. PD-L1 antibody stained section of the granulomatous inflammation shows strong
membranous staining of the histiocytes within the granulomas and scattered positive lymphocytes (a, 4×; b, 20×)
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[16]. Our patient had mediastinal and left hilar lymphaden-
opathy on baseline scans with FDG-uptake comparable
with other lesions. The mediastinal and hilar lymph nodes
did not respond to immunotherapy treatment, despite re-
sponse in all other sites present on baseline evaluation, and
the adenopathy progressed with the development of the
biopsy-proven cutaneous sarcoid lesions. FNA of the sub-
carinal lymph node present prior to treatment demon-
strated granulomatous inflammation, raising the likelihood
that the sarcoid process had already started prior to initi-
ation of immunotherapy.
The clinical manifestations of sarcoidosis are diverse,
most commonly with pulmonary and cutaneous findings,
and are patient-specific with no pathognomonic pattern
[16]. As the clinical findings can vary greatly and can
occur long after immune therapy is completed, clinicians
must be aware of the possibility of granuloma formation
that mimics metastatic disease on imaging and examin-
ation. Tissue remains the gold standard for diagnosis.
Sarcoidosis is a multi-system granulomatous disorder of
unclear etiology characterized by the presence of CD4+
Th1-like cells that initiate granuloma formation in various
tissues [22]. These CD4+ Th1 cells secrete predominantly
interleukin-2 and interferon-γ to enhance macrophage
TNF-α production which results in a compartmentalized
accumulation of multinucleated giant cells and epithelioid
cells surrounded by CD8+ T-cells, regulatory T-cells, and
fibroblasts [22, 23]. Th17 cells are a subset of CD4+ ef-
fector T cells that produce inteleukin-17 and are linked
with tissue inflammation and autoimmunity [23–25]. Von
Euw et al. demonstrated that treatment with the anti-
CTLA4 antibody tremelimumab resulted in an increase in
Th17 CD4+ cells in peripheral blood [25]. Patients with
irAEs from tremelimumab therapy showed an increase in
Th17 cells in their post-treatment blood assessments. In a
potential link with anti-CTLA4 therapy and sarcoidosis
development, bronchoalveolar lavage samples and lung bi-
opsy specimens from patients with sarcoidosis also con-
tain high numbers of Th17 effector CD4+ cells [23, 24].
PD-L1 staining on the sarcoid tissue from our patient
was diffusely positive. In 2014, Braun et al. demonstrated
increased expression of PD-1 on CD4+ T cells in both
peripheral blood and BAL fluid samples from patients
with sarcoidosis [26]. There was also upregulation of
PD-L1 in sarcoid granulomas. The authors further
showed that blockade of the PD-1 pathway, in vitro, re-
stored the proliferative capacity of sarcoid CD4+ cells to
the normal range, a pattern seen in spontaneous clinical
resolution of sarcoidosis. Consistent with this, Xu et al.
also demonstrated diffuse, strong, membranous positiv-
ity for PD-L1 in 100% and PD-L2 positivity in 86% of
evaluated sarcoidosis cases [27]. These results suggest a
possible therapeutic role for anti-PD-1 therapy in pa-
tients with sarcoidosis, though this idea is countered by
the cases of sarcoid development in the setting of nivo-
lumab and pembrolizumab therapy. Additional research
into these questions will be necessary to fully understand
the relative role of these therapeutic agents in the cause
and management of sarcoidosis.
In our case, there were multiple variables contributing
to the clinical scenario and the driver for the sarcoid
progression was unclear. She had received both ipilimu-
mab and nivolumab in combination around the time of
the clinical change, but in retrospect also likely had sar-
coidosis at baseline. We opted for a break in treatment
to allow a period of observation without further im-
munotherapy or initiation of steroids. In 2016, Johnson
et al. detailed the use of ipilimumab in a series of 30 pa-
tients with pre-existing autoimmune disease, including
two patients with underlying sarcoidosis [28]. One of
these patients experienced a sarcoid-exacerbation with
hypercalcemia and renal insufficiency managed with ste-
roids and the other patient developed an ocular irAE
managed with topical steroids. Our patient had no clin-
ical or radiographic change on observation and after dis-
cussion of the risks and benefits we elected to continue
with nivolumab. To date, there has been neither change
in her lymphadenopathy nor the development of any
evidence of progression of sarcoidosis or melanoma.
With routine use of combination and sequential anti-
CTLA-4 and anti-PD1 therapy in melanoma patients,
this clinical scenario will likely be encountered with
more frequency and providers will be challenged to de-
cide on appropriate anti-melanoma therapy.
In our patient with known metastatic melanoma, had
biopsies not been performed the growth of sarcoid
would have erroneously led to the conclusion that dis-
ease had progressed, which may have resulted in prema-
ture cessation of therapy. The differential for new
mediastinal adenopathy and cutaneous lesions in melan-
oma patients on combination ipilimumab/nivolumab im-
munotherapy should include sarcoidosis. Biopsy for
evaluation of new lesions developing on immunotherapy,
particularly in the setting of mixed responses, is favored
to help guide decision making. Continued anti-PD1 ther-
apy can be considered for appropriate patients with close
observation.
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